Excision BioTherapeutics

Daniel Dornbusch, CEO 

Oct. 13 | 11:30am | Oxford Biomedica Ballroom 

San Francisco, CA 

(Private) 

In-person Presentation 

Excision BioTherapeutics is a biotechnology company developing CRISPR-based therapies as potential cures for viral infectious diseases. Excision unites next-generation CRISPR nucleases with a novel gene editing approach and has become the first and only company in history to cure HIV with a therapeutic in an animal model. EBT-101, the company’s lead program intended to cure HIV with a single IV infusion, is being evaluated in clinical trials. Excision’s pipeline includes one-time potential cures for herpes virus, JC virus, which causes PML, and hepatitis B virus. The company’s foundational technologies were developed in the laboratories of Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at the University of California, Berkeley. 

www.excision.bio 



By using this website you agree to accept our Privacy Policy and Terms & Conditions